Review Article
Split Viewer
Blood Res 2021; 56(S1):
Published online April 30, 2021
https://doi.org/10.5045/br.2021.2021049
© The Korean Society of Hematology
Genomics of diffuse large B cell lymphoma
Correspondence to : Youngil Koh, M.D.
Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul 03080, Korea
E-mail: go01@snu.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Next generation sequencing (NGS) technology has revealed the heterogeneity of diffuse large B-cell lymphoma (DLBCL) from a mutation perspective. Accordingly, the conventional cell of origin-based classification of DLBCL has changed to a mutation-based classification. Mutation analysis delineates that B-cell receptor pathway activation, EZH2 mutation, and NOTCH mutations are distinctive drivers of DLBCL. Moreover, the combination of RNA expression data and DNA mutation results suggests similarity between DLBCL subtypes and other non-Hodgkin lymphomas. NGS-based dissection of DLBCL would be the cornerstone for precision treatment in this heterogeneous disease in the near future.
Keywords DLBCL, NGS, RNA, Clustering, Classification, Genomics
PDF
Standard view
Export citation
Share Article
Review Article
Blood Res 2021; 56(S1): S75-S79
Published online April 30, 2021 https://doi.org/10.5045/br.2021.2021049
Copyright © The Korean Society of Hematology.
Genomics of diffuse large B cell lymphoma
Youngil Koh
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
Correspondence to:Youngil Koh, M.D.
Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul 03080, Korea
E-mail: go01@snu.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Next generation sequencing (NGS) technology has revealed the heterogeneity of diffuse large B-cell lymphoma (DLBCL) from a mutation perspective. Accordingly, the conventional cell of origin-based classification of DLBCL has changed to a mutation-based classification. Mutation analysis delineates that B-cell receptor pathway activation, EZH2 mutation, and NOTCH mutations are distinctive drivers of DLBCL. Moreover, the combination of RNA expression data and DNA mutation results suggests similarity between DLBCL subtypes and other non-Hodgkin lymphomas. NGS-based dissection of DLBCL would be the cornerstone for precision treatment in this heterogeneous disease in the near future.
Keywords: DLBCL, NGS, RNA, Clustering, Classification, Genomics
Fig 1.
Download
Fig 2.
Download
Fig 3.
Download
Fig 4.
Download
Fig 5.
Download
Fig 6.
Download
Previous Article
Article Tools
Stats or Metrics
Share this article on
Related articles in BR
-
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
Naree Warnnissorn, Nonglak Kanitsap, Pimjai Niparuck, Paisarn Boonsakan, Prapasri Kulalert, Wasithep Limvorapitak, Lantarima Bhoopat, Supawee Saengboon, Chinnawut Suriyonplengsaeng, Pichika Chantrathammachart, Teeraya Puavilai and Suporn Chuncharunee
Blood Res 2024; 59(): -
Classification of acute myeloid leukemia
Sang Mee Hwang
Blood Res 2020; 55(S1): S1-S4 -
Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma
Do-Young Kim, Moo-Kon Song, Joo-Seop Chung, Ho-Jin Shin, Deok Hwan Yang, Sung-Nam Lim, Sung-Yong Oh
Blood Res 2019; 54(4): 244-252
